Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

A promising approach of overcoming the intrinsic resistance of Candida krusei to fluconazole (FLC)--combining tacrolimus with FLC.

Li H, Zhang C, Chen Z, Shi W, Sun S.

FEMS Yeast Res. 2014 Aug;14(5):808-11. doi: 10.1111/1567-1364.12163. Epub 2014 Jun 12.

2.

Resistance reversal induced by a combination of fluconazole and tacrolimus (FK506) in Candida glabrata.

Li H, Chen Z, Zhang C, Gao Y, Zhang X, Sun S.

J Med Microbiol. 2015 Jan;64(Pt 1):44-52. doi: 10.1099/jmm.0.081760-0. Epub 2014 Oct 29.

PMID:
25355935
3.

Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.

Spreghini E, Maida CM, Tomassetti S, Orlando F, Giannini D, Milici ME, Scalise G, Barchiesi F.

Antimicrob Agents Chemother. 2008 Jun;52(6):1929-33. doi: 10.1128/AAC.00130-08. Epub 2008 Apr 7.

4.

In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans.

Guo N, Ling G, Liang X, Jin J, Fan J, Qiu J, Song Y, Huang N, Wu X, Wang X, Deng X, Deng X, Yu L.

Mycoses. 2011 Sep;54(5):e400-6. doi: 10.1111/j.1439-0507.2010.01935.x. Epub 2010 Jul 18.

PMID:
21910756
5.

Candida and candidaemia. Susceptibility and epidemiology.

Arendrup MC.

Dan Med J. 2013 Nov;60(11):B4698. Review.

PMID:
24192246
6.

In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species.

Pfaller MA, Rhomberg PR, Messer SA, Castanheira M.

Diagn Microbiol Infect Dis. 2015 Apr;81(4):259-63. doi: 10.1016/j.diagmicrobio.2014.11.008. Epub 2014 Nov 25.

PMID:
25600842
7.

Synergistic antifungal activity of berberine derivative B-7b and fluconazole.

Li LP, Liu W, Liu H, Zhu F, Zhang DZ, Shen H, Xu Z, Qi YP, Zhang SQ, Chen SM, He LJ, Cao XJ, Huang X, Zhang JD, Yan L, An MM, Jiang YY.

PLoS One. 2015 May 19;10(5):e0126393. doi: 10.1371/journal.pone.0126393. eCollection 2015.

8.

In vitro synergy of eugenol and methyleugenol with fluconazole against clinical Candida isolates.

Ahmad A, Khan A, Khan LA, Manzoor N.

J Med Microbiol. 2010 Oct;59(Pt 10):1178-84. doi: 10.1099/jmm.0.020693-0. Epub 2010 Jul 15.

PMID:
20634332
9.
10.

Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans.

Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D.

Antimicrob Agents Chemother. 2000 Sep;44(9):2373-81.

11.

Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.

Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA.

J Clin Microbiol. 2006 Feb;44(2):324-6.

12.

The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms.

Jia W, Zhang H, Li C, Li G, Liu X, Wei J.

BMC Microbiol. 2016 Jun 18;16(1):113. doi: 10.1186/s12866-016-0728-1.

13.

In vitro evaluation of the acquisition of resistance, antifungal activity and synergism of Brazilian red propolis with antifungal drugs on Candida spp.

Pippi B, Lana AJ, Moraes RC, Güez CM, Machado M, de Oliveira LF, Lino von Poser G, Fuentefria AM.

J Appl Microbiol. 2015 Apr;118(4):839-50. doi: 10.1111/jam.12746. Epub 2015 Feb 4.

PMID:
25565139
14.

Distribution and antifungal susceptibility of Candida species causing nosocomial candiduria.

Ozhak-Baysan B, Ogunc D, Colak D, Ongut G, Donmez L, Vural T, Gunseren F.

Med Mycol. 2012 Jul;50(5):529-32. doi: 10.3109/13693786.2011.618996. Epub 2011 Oct 11.

PMID:
21988703
15.

Synergistic antifungal effect of glabridin and fluconazole.

Liu W, Li LP, Zhang JD, Li Q, Shen H, Chen SM, He LJ, Yan L, Xu GT, An MM, Jiang YY.

PLoS One. 2014 Jul 24;9(7):e103442. doi: 10.1371/journal.pone.0103442. eCollection 2014.

16.

Antifungal activity of Rubus chingii extract combined with fluconazole against fluconazole-resistant Candida albicans.

Han B, Chen J, Yu YQ, Cao YB, Jiang YY.

Microbiol Immunol. 2016 Feb;60(2):82-92. doi: 10.1111/1348-0421.12357.

17.

Synergistic and drug-resistant reversing effects of diorcinol D combined with fluconazole against Candida albicans.

Li Y, Chang W, Zhang M, Li X, Jiao Y, Lou H.

FEMS Yeast Res. 2015 Mar;15(2). pii: fov001. doi: 10.1093/femsyr/fov001. Epub 2015 Mar 8.

PMID:
25752309
18.

In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei.

Ricardo E, Miranda IM, Faria-Ramos I, Silva RM, Rodrigues AG, Pina-Vaz C.

Antimicrob Agents Chemother. 2014 Aug;58(8):4604-11. doi: 10.1128/AAC.02603-14. Epub 2014 May 27.

19.

Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?

Kovacicova G, Krupova Y, Lovaszova M, Roidova A, Trupl J, Liskova A, Hanzen J, Milosovic P, Lamosova M, Macekova L, Szovenyiova Z, Purgelova A, Obertik T, Bille J, Krcmery V.

J Infect Chemother. 2000 Dec;6(4):216-21.

PMID:
11810569
20.

[In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].

Rubio Calvo MC, Gil J, Ramírez de Ocáriz I, Benito R, Rezusta A.

Rev Esp Quimioter. 2003 Jun;16(2):227-32. Spanish.

Supplemental Content

Support Center